Clinical

Managing Hypertension in the Elderly: A Common Chronic Disease with Increasing Age

Scott R. Anderson, MS IV, Lindsay Sanders, DO, MPH, Loida D. Nguyen, PharmD, BCPS, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

Improving Hypertension Management in the Elderly a Core Clinical Goal

by Katrina Moore, PharmD

Clinical

Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty

Richard J. Friedman, MD, FRCSC

Stakeholder Perspective

A Paradigm Shift in Anticoagulation?

by Atheer A. Kaddis, PharmD

Clinical

Daily Average Consumption of 2 Long-Acting Opioids: An Interrupted Time Series Analysis

R. Amy Puenpatom, PhD, Sheryl L. Szeinbach, PhD, RPh, Larry Ma, PhD, Rami H. Ben-Joseph, PhD, Kent H. Summers, PhD, BSPharm

Stakeholder Perspective

Daily Average Consumption of 2 Long-Acting Opioids and Coverage Decisions

by Matthew Mitchell, PharmD, MBA, FAMCP

Clinical

Impact of Treatment by NCQA-Certified Physicians on Diabetes-Related Outcomes

Brett Pinsky, MPH, James Harnett, PharmD, Ryne Paulose-Ram, PhD, Jack Mardekian, PhD, Navendu Samant, PhD, Kavita V. Nair, PhD

Stakeholder Perspective

What Certification Really Means for Physician Quality

by Walid F. Gellad, MD, MPH

Clinical

The Hickory Project: Controlling Healthcare Costs and Improving Outcomes for Diabetes Using the Asheville Project Model

Barry A. Bunting, PharmD, DSNAP, Grover Lee, PharmD, BCMCM, Grant Knowles, PharmD, Christine Lee, PharmD, BCPS, CLS, Paul Allen, PhD, MBA

Stakeholder Perspective

Keeping a Lid on Health Plan Costs, One Patient at a Time

by Rick Miller

Clinical

A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America

Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS, Vahram Ghushchyan, PhD, Kavita Nair, PhD

Stakeholder Perspective

Prevention Efforts before Disease Strikes the Key to a Healthy Population of Young Adults

by James T. Kenney, RPh, MBA

Clinical

Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications

Henry J. Riordan, PhD, Paola Antonini, MD, PhD, Michael F. Murphy, MD, PhD

Stakeholder Perspective

The Complexities of Treating Mental Illness

by Atheer A. Kaddis, PharmD

Clinical

Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes

Karmella T. Thomas, BS, RD, Katie B. Lyons, MS II, Loida D. Nguyen, PharmD, BCPS, Raymond A. Plodkowski, MD, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

New Therapies with Novel Mechanisms of Action Are Urgently Needed for Type 2 Diabetes

by James V. Felicetta, MD

Clinical

Lipid Management in Patients with Type 2 Diabetes

Marsha J. Daniel, PharmD, cPh, CDE

Stakeholder Perspective

The Time Is Now to Promote Aggressive Lipid Management to Prevent Macrovascular Complications in Patients with Type 2 Diabetes

by Gary M. Owens, MD

Clinical

JAK Inhibitor Improves Response, Symptoms in Patients with High-Risk Myelofibrosis

Page 10 of 14
Results 91 - 100 of 131